ASSC Genetics Summit, 21 March 2022
Inherited variation at multiple genes plays a major role in determining who develops cutaneous melanoma, and the risk from these genes can be combined as a polygenic risk score. The use of polygenic risk scores in chronic diseases and cancers is a rapidly evolving field, and questions remain about their potential value in disease prediction and management. Generating a consensus roadmap that outlines the role for polygenic risk scores in melanoma management is challenging yet critical.
The Australian Skin and Skin Cancer Research Centre (ASSC) is hosting the Genetics Summit, on 21 March, 2022, at the Translational Research Institute. This invitation-only meeting in Brisbane will bring together multiple stakeholder groups (including researchers, NGOs, government agencies, specialist colleges, clinicians, and consumers) to review the latest evidence in this debate.
- Date: Monday 21 March, 2022
- Location: Translational Research Institute (TRI), Brisbane, Australia
We hope you can join us for this exciting event where we will work together to generate a consensus on the use of polygenic risk scores in melanoma.
Dr Aideen McInerney-Leo & Associate Professor Matthew Law
On behalf of the ASSC Genetics Summit Organising Committee:
Professor Anne Cust (The University of Sydney)
Professor Monika Janda (The University of Queensland)
Associate Professor Matthew Law (QIMR Berghofer Medical Research Institute)
Dr Aideen McInerney-Leo (The University of Queensland)
Dr Amy Nisselle (Murdoch Children’s Research Institute)
Professor H. Peter Soyer (The University of Queensland)
Professor David Whiteman (QIMR Berghofer Medical Research Institute)
Dr Tatiane Yanes (The University of Queensland)
|The ASSC is a joint collaboration of skin and skin cancer researchers at The University of Queensland and QIMR Berghofer Medical Research Institute. The Genetics Summit follows the success of previous ASSC Summits: the Sunscreen Summit in March 2018, which achieved revisions to sunscreen policy in Australia and New Zealand; the Melanoma Screening Summit in 2019, developed a new consensus statement regarding the approach needed for national screening for melanoma; and the Sun Exposure Summit, in 2021.|